Market open
Longboard Pharmaceuticals/$LBPH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Ticker
$LBPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
50
Website
LBPH Metrics
BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$2.23
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$2.3B
Beta
1.09
52-week high
$59.77
52-week low
$3.60
Average daily volume
2.8M
Financial strength
Current ratio
15.967
Quick ratio
15.717
Long term debt to equity
1.26
Total debt to equity
1.357
Management effectiveness
Return on assets (TTM)
-30.72%
Return on equity (TTM)
-46.66%
Valuation
Price to book
8.48
Price to tangible book (TTM)
8.48
Price to free cash flow (TTM)
-31.09
Growth
Earnings per share change (TTM)
-7.73%
3-year earnings per share growth (CAGR)
-5.30%
What the Analysts think about LBPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Longboard Pharmaceuticals stock.
LBPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LBPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LBPH News
AllArticlesVideos
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
Business Wire·3 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
GlobeNewsWire·1 month ago
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Longboard Pharmaceuticals stock?
Longboard Pharmaceuticals (LBPH) has a market cap of $2.3B as of November 21, 2024.
What is the P/E ratio for Longboard Pharmaceuticals stock?
The price to earnings (P/E) ratio for Longboard Pharmaceuticals (LBPH) stock is 0 as of November 21, 2024.
Does Longboard Pharmaceuticals stock pay dividends?
No, Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders as of November 21, 2024.
When is the next Longboard Pharmaceuticals dividend payment date?
Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Longboard Pharmaceuticals?
Longboard Pharmaceuticals (LBPH) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.